Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Paragon Capital Management Inc.

Paragon Capital Management Inc. grew its position in Royalty Pharma plc (NASDAQ:RPRX) by 328.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 70,339 shares of the biopharmaceutical company’s stock after acquiring an additional 53,937 shares during the period. Royalty Pharma comprises approximately 1.4% of Paragon Capital Management Inc.’s investment portfolio, making the stock its 18th biggest position. Paragon Capital Management Inc.’s holdings in Royalty Pharma were worth $1,794,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Brooklyn Investment Group raised its position in shares of Royalty Pharma by 1,006.9% in the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 876 shares during the period. Blue Trust Inc. increased its stake in shares of Royalty Pharma by 362.7% during the third quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 943 shares in the last quarter. Fifth Third Bancorp increased its stake in shares of Royalty Pharma by 187.1% during the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 997 shares in the last quarter. Spire Wealth Management increased its stake in shares of Royalty Pharma by 377.6% during the fourth quarter. Spire Wealth Management now owns 2,149 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 1,699 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Royalty Pharma during the third quarter worth about $61,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Down 0.2 %

RPRX stock opened at $31.26 on Wednesday. Royalty Pharma plc has a one year low of $24.05 and a one year high of $32.21. The stock has a market capitalization of $18.42 billion, a PE ratio of 16.20 and a beta of 0.49. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54. The company has a fifty day moving average of $27.43 and a 200-day moving average of $27.55.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be paid a $0.22 dividend. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date is Friday, February 21st. This represents a $0.88 annualized dividend and a dividend yield of 2.82%. Royalty Pharma’s dividend payout ratio (DPR) is 43.52%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Citigroup cut their target price on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th. TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. Finally, StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.